| Survival Probability in % (95% Confidence Interval) | ||||||||||
| Test Population | White | Black | Other | Unkown | ||||||
| n | % | n | % | n | % | n | % | n | % | |
| 5-Year Survival | ||||||||||
| All Cases | 3,096 | 65.8% | 2555 | 65.9% | 195 | 63.3% | 332 | 66.2% | 14 | 81.5% |
| Age at diagnosis | ||||||||||
| 0 - 19 years | 1418 | 78.6% | 1167 | 78.9% | 114 | 72.7% | 131 | 80.3% | 6 | 100.0% |
| 20 - 39 years | 875 | 59.1% | 710 | 59.3% | 45 | 56.5% | 114 | 59.2% | 6 | -- |
| 40 - 59 years | 677 | 50.8% | 568 | 50.5% | 32 | 43.4% | 75 | 55.6% | 2 | 100.0% |
| >60 years | 126 | 34.2% | 110 | 35.9% | 4 | 0.0% | 12 | 32.1% | 0 | -- |
| Sex | ||||||||||
| Male | 1952 | 66.0% | 1626 | 65.8% | 111 | 60.2% | 206 | 70.3% | 9 | 70.0% |
| Female | 1144 | 65.5% | 929 | 66.0% | 84 | 67.2% | 126 | 59.6% | 5 | 100.0% |
| All phenotypes | ||||||||||
| T-cell | 702 | 77.4% | 536 | 78.9% | 77 | 70.0% | 87 | 74.5% | 2 | 100.0% |
| B-cell | 1909 | 61.3% | 1623 | 61.7% | 90 | 55.6% | 189 | 60.4% | 7 | 83.3% |
| Unknown lineage | 225 | 64.7% | 188 | 62.5% | 15 | 73.3% | 21 | 76.2% | 1 | 100.0% |
| Other | 260 | 80.8% | 208 | 80.8% | 13 | -- | 35 | -- | 4 | -- |
| 10-Year Survival | ||||||||||
| All Cases | 3096 | 60.9% | 2555 | 60.9% | 195 | 60.1% | 332 | 60.7% | 14 | 81.5% |
| Age at diagnosis | ||||||||||
| 0 - 19 years | 1418 | 75.1% | 1167 | 75.1% | 114 | 71.7% | 131 | 77.0% | 6 | 100.0% |
| 20 - 39 years | 875 | 54.5% | 710 | 54.8% | 45 | 50.3% | 114 | 54.4% | 6 | -- |
| 40 - 59 years | 677 | 41.8% | 568 | 42.2% | 32 | 27.9% | 75 | 43.6% | 2 | -- |
| >60 years | 126 | 22.5% | 110 | 22.9% | 4 | 0.0% | 12 | 32.1% | 0 | -- |
| Sex | ||||||||||
| Male | 1952 | 60.7% | 1626 | 60.6% | 111 | 56.2% | 206 | 64.3% | 9 | 70.0% |
| Female | 1144 | 61.1% | 929 | 61.4% | 84 | 65.1% | 126 | 54.9% | 5 | -- |
| All phenotypes | ||||||||||
| T-cell | 702 | 75.0% | 536 | 76.5% | 77 | 70.0% | 87 | 69.2% | 2 | 100.0% |
| B-cell | 1909 | 55.4% | 1623 | 55.6% | 90 | 50.1% | 189 | 55.3% | 7 | -- |
| Unknown lineage | 225 | 60.0% | 188 | 58.5% | 15 | 66.7% | 21 | 66.7% | 1 | 100.0% |
| Other | 260 | 64.7% | 208 | 64.6% | 13 | -- | 35 | -- | 4 | -- |